nodes	percent_of_prediction	percent_of_DWPC	metapath
Epinephrine—SLC22A1—hematologic cancer	0.149	0.581	CbGaD
Epinephrine—L-DOPA—Melphalan—hematologic cancer	0.125	1	CrCrCtD
Epinephrine—TNF—hematologic cancer	0.107	0.419	CbGaD
Epinephrine—TNF—Thalidomide—hematologic cancer	0.07	0.192	CbGbCtD
Epinephrine—SLC22A2—Daunorubicin—hematologic cancer	0.0189	0.0517	CbGbCtD
Epinephrine—SLC22A2—Cytarabine—hematologic cancer	0.0167	0.0456	CbGbCtD
Epinephrine—SLC22A2—Cladribine—hematologic cancer	0.0157	0.0431	CbGbCtD
Epinephrine—SLC22A1—Cytarabine—hematologic cancer	0.0145	0.0396	CbGbCtD
Epinephrine—SLC22A2—Imatinib—hematologic cancer	0.0145	0.0396	CbGbCtD
Epinephrine—CYP1A2—Anagrelide—hematologic cancer	0.0142	0.0387	CbGbCtD
Epinephrine—SLC22A1—Cladribine—hematologic cancer	0.0137	0.0374	CbGbCtD
Epinephrine—SLC22A1—Imatinib—hematologic cancer	0.0126	0.0344	CbGbCtD
Epinephrine—CYP2C9—Bexarotene—hematologic cancer	0.00884	0.0242	CbGbCtD
Epinephrine—SLC22A2—Vinblastine—hematologic cancer	0.00804	0.022	CbGbCtD
Epinephrine—CYP1A2—Carmustine—hematologic cancer	0.00744	0.0203	CbGbCtD
Epinephrine—SLC22A2—Cisplatin—hematologic cancer	0.00737	0.0202	CbGbCtD
Epinephrine—CYP2C9—Idarubicin—hematologic cancer	0.00733	0.02	CbGbCtD
Epinephrine—CYP1A2—Methoxsalen—hematologic cancer	0.00632	0.0173	CbGbCtD
Epinephrine—CYP1A2—Bortezomib—hematologic cancer	0.00601	0.0165	CbGbCtD
Epinephrine—CYP1A2—Daunorubicin—hematologic cancer	0.00575	0.0157	CbGbCtD
Epinephrine—CYP1A2—Alitretinoin—hematologic cancer	0.00564	0.0154	CbGbCtD
Epinephrine—CYP2C9—Bortezomib—hematologic cancer	0.00542	0.0148	CbGbCtD
Epinephrine—CYP1A2—Thalidomide—hematologic cancer	0.00524	0.0143	CbGbCtD
Epinephrine—CYP3A4—Bexarotene—hematologic cancer	0.00514	0.0141	CbGbCtD
Epinephrine—CYP3A4—Lomustine—hematologic cancer	0.00478	0.0131	CbGbCtD
Epinephrine—CYP3A4—Busulfan—hematologic cancer	0.00478	0.0131	CbGbCtD
Epinephrine—CYP2C9—Thalidomide—hematologic cancer	0.00472	0.0129	CbGbCtD
Epinephrine—CYP1A2—Dacarbazine—hematologic cancer	0.00451	0.0123	CbGbCtD
Epinephrine—CYP2C9—Teniposide—hematologic cancer	0.0045	0.0123	CbGbCtD
Epinephrine—CYP1A2—Imatinib—hematologic cancer	0.00441	0.0121	CbGbCtD
Epinephrine—CYP3A4—Thiotepa—hematologic cancer	0.00426	0.0117	CbGbCtD
Epinephrine—CYP2C9—Ifosfamide—hematologic cancer	0.00416	0.0114	CbGbCtD
Epinephrine—CYP2C9—Imatinib—hematologic cancer	0.00397	0.0109	CbGbCtD
Epinephrine—CYP2C9—Nilotinib—hematologic cancer	0.00361	0.00987	CbGbCtD
Epinephrine—CYP1A2—Dasatinib—hematologic cancer	0.00354	0.00968	CbGbCtD
Epinephrine—CYP3A4—Methoxsalen—hematologic cancer	0.00331	0.00906	CbGbCtD
Epinephrine—CYP3A4—Bortezomib—hematologic cancer	0.00315	0.00862	CbGbCtD
Epinephrine—CYP3A4—Daunorubicin—hematologic cancer	0.00301	0.00825	CbGbCtD
Epinephrine—CYP3A4—Cytarabine—hematologic cancer	0.00266	0.00727	CbGbCtD
Epinephrine—CYP3A4—Teniposide—hematologic cancer	0.00262	0.00717	CbGbCtD
Epinephrine—CYP3A4—Ifosfamide—hematologic cancer	0.00242	0.00661	CbGbCtD
Epinephrine—CYP3A4—Imatinib—hematologic cancer	0.00231	0.00632	CbGbCtD
Epinephrine—CYP1A2—Etoposide—hematologic cancer	0.0022	0.00603	CbGbCtD
Epinephrine—CYP3A4—Ruxolitinib—hematologic cancer	0.00217	0.00595	CbGbCtD
Epinephrine—CYP3A4—Nilotinib—hematologic cancer	0.0021	0.00574	CbGbCtD
Epinephrine—CYP3A4—Vinorelbine—hematologic cancer	0.00208	0.00569	CbGbCtD
Epinephrine—CYP2C9—Cisplatin—hematologic cancer	0.00202	0.00553	CbGbCtD
Epinephrine—PAH—hematopoietic system—hematologic cancer	0.00199	0.0977	CbGeAlD
Epinephrine—CYP3A4—Triamcinolone—hematologic cancer	0.0019	0.00521	CbGbCtD
Epinephrine—CYP3A4—Dasatinib—hematologic cancer	0.00185	0.00507	CbGbCtD
Epinephrine—CYP3A4—Mitoxantrone—hematologic cancer	0.00183	0.00501	CbGbCtD
Epinephrine—TNF—blood—hematologic cancer	0.00176	0.086	CbGeAlD
Epinephrine—CYP2C9—Dexamethasone—hematologic cancer	0.00163	0.00447	CbGbCtD
Epinephrine—CYP3A4—Betamethasone—hematologic cancer	0.00163	0.00447	CbGbCtD
Epinephrine—CYP3A4—Prednisolone—hematologic cancer	0.00161	0.00441	CbGbCtD
Epinephrine—ADRBK1—hematopoietic system—hematologic cancer	0.00152	0.0746	CbGeAlD
Epinephrine—CYP3A4—Prednisone—hematologic cancer	0.00152	0.00416	CbGbCtD
Epinephrine—CYP3A4—Irinotecan—hematologic cancer	0.00144	0.00395	CbGbCtD
Epinephrine—PAH—blood—hematologic cancer	0.00132	0.0647	CbGeAlD
Epinephrine—CYP3A4—Vinblastine—hematologic cancer	0.00128	0.00351	CbGbCtD
Epinephrine—CYP3A4—Vincristine—hematologic cancer	0.00126	0.00345	CbGbCtD
Epinephrine—L-DOPA—PSIP1—hematologic cancer	0.00117	0.538	CrCbGaD
Epinephrine—ADRBK1—gonad—hematologic cancer	0.00116	0.0567	CbGeAlD
Epinephrine—CYP3A4—Etoposide—hematologic cancer	0.00115	0.00316	CbGbCtD
Epinephrine—TNF—lymph node—hematologic cancer	0.00105	0.0516	CbGeAlD
Epinephrine—ADRBK1—blood—hematologic cancer	0.00101	0.0494	CbGeAlD
Epinephrine—ADRBK1—bone marrow—hematologic cancer	0.000976	0.0478	CbGeAlD
Epinephrine—CYP3A4—Dexamethasone—hematologic cancer	0.00095	0.0026	CbGbCtD
Epinephrine—ADRBK1—lung—hematologic cancer	0.000884	0.0433	CbGeAlD
Epinephrine—ADRBK1—testis—hematologic cancer	0.000834	0.0409	CbGeAlD
Epinephrine—CYP3A4—Doxorubicin—hematologic cancer	0.000788	0.00216	CbGbCtD
Epinephrine—Isoprenaline—PIK3R1—hematologic cancer	0.000724	0.334	CrCbGaD
Epinephrine—ADRBK1—lymph node—hematologic cancer	0.000605	0.0296	CbGeAlD
Epinephrine—ADRA1A—hematopoietic system—hematologic cancer	0.000503	0.0247	CbGeAlD
Epinephrine—SLC22A1—blood—hematologic cancer	0.000438	0.0215	CbGeAlD
Epinephrine—CYP1A2—hematopoietic system—hematologic cancer	0.000416	0.0204	CbGeAlD
Epinephrine—CYP2C9—hematopoietic system—hematologic cancer	0.000395	0.0194	CbGeAlD
Epinephrine—ADRA2A—hematopoietic system—hematologic cancer	0.000383	0.0188	CbGeAlD
Epinephrine—ADRB1—lung—hematologic cancer	0.00037	0.0181	CbGeAlD
Epinephrine—ADRA1A—blood—hematologic cancer	0.000334	0.0163	CbGeAlD
Epinephrine—ADRA2C—blood—hematologic cancer	0.000318	0.0156	CbGeAlD
Epinephrine—SLC22A5—blood—hematologic cancer	0.000304	0.0149	CbGeAlD
Epinephrine—CYP3A4—hematopoietic system—hematologic cancer	0.000301	0.0148	CbGeAlD
Epinephrine—ADRA2A—gonad—hematologic cancer	0.000291	0.0143	CbGeAlD
Epinephrine—ADRA2C—lung—hematologic cancer	0.000279	0.0136	CbGeAlD
Epinephrine—CYP1A2—blood—hematologic cancer	0.000276	0.0135	CbGeAlD
Epinephrine—SLC22A5—lung—hematologic cancer	0.000267	0.0131	CbGeAlD
Epinephrine—ADRA2C—testis—hematologic cancer	0.000263	0.0129	CbGeAlD
Epinephrine—CYP2C9—blood—hematologic cancer	0.000262	0.0128	CbGeAlD
Epinephrine—ADRA2A—blood—hematologic cancer	0.000254	0.0124	CbGeAlD
Epinephrine—SLC22A5—testis—hematologic cancer	0.000252	0.0123	CbGeAlD
Epinephrine—CYP1A2—lung—hematologic cancer	0.000242	0.0118	CbGeAlD
Epinephrine—ADRA2A—lung—hematologic cancer	0.000222	0.0109	CbGeAlD
Epinephrine—ADRA2A—testis—hematologic cancer	0.00021	0.0103	CbGeAlD
Epinephrine—CYP3A4—blood—hematologic cancer	0.0002	0.00978	CbGeAlD
Epinephrine—ADRA2C—lymph node—hematologic cancer	0.000191	0.00933	CbGeAlD
Epinephrine—SLC22A5—lymph node—hematologic cancer	0.000183	0.00894	CbGeAlD
Epinephrine—ADRA2A—lymph node—hematologic cancer	0.000152	0.00745	CbGeAlD
Epinephrine—Norepinephrine—SLC22A1—hematologic cancer	0.000144	0.0665	CrCbGaD
Epinephrine—Dopamine—SLC22A1—hematologic cancer	0.000134	0.0618	CrCbGaD
Epinephrine—Haemoglobin—Betamethasone—hematologic cancer	4.86e-05	0.000375	CcSEcCtD
Epinephrine—Cerebrovascular accident—Epirubicin—hematologic cancer	4.86e-05	0.000375	CcSEcCtD
Epinephrine—Vomiting—Cladribine—hematologic cancer	4.86e-05	0.000375	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Thalidomide—hematologic cancer	4.86e-05	0.000375	CcSEcCtD
Epinephrine—Hyperhidrosis—Irinotecan—hematologic cancer	4.86e-05	0.000375	CcSEcCtD
Epinephrine—Hyperhidrosis—Mitoxantrone—hematologic cancer	4.86e-05	0.000375	CcSEcCtD
Epinephrine—Paraesthesia—Carmustine—hematologic cancer	4.85e-05	0.000374	CcSEcCtD
Epinephrine—Dizziness—Vinblastine—hematologic cancer	4.85e-05	0.000374	CcSEcCtD
Epinephrine—Insomnia—Alitretinoin—hematologic cancer	4.84e-05	0.000373	CcSEcCtD
Epinephrine—Haemorrhage—Betamethasone—hematologic cancer	4.84e-05	0.000373	CcSEcCtD
Epinephrine—Haemorrhage—Dexamethasone—hematologic cancer	4.84e-05	0.000373	CcSEcCtD
Epinephrine—Hallucination—Dexamethasone—hematologic cancer	4.82e-05	0.000371	CcSEcCtD
Epinephrine—Hallucination—Betamethasone—hematologic cancer	4.82e-05	0.000371	CcSEcCtD
Epinephrine—Paraesthesia—Alitretinoin—hematologic cancer	4.81e-05	0.000371	CcSEcCtD
Epinephrine—Somnolence—Carmustine—hematologic cancer	4.8e-05	0.00037	CcSEcCtD
Epinephrine—Nervous system disorder—Gemcitabine—hematologic cancer	4.8e-05	0.00037	CcSEcCtD
Epinephrine—Arrhythmia—Triamcinolone—hematologic cancer	4.76e-05	0.000368	CcSEcCtD
Epinephrine—Somnolence—Alitretinoin—hematologic cancer	4.76e-05	0.000367	CcSEcCtD
Epinephrine—Skin disorder—Gemcitabine—hematologic cancer	4.75e-05	0.000367	CcSEcCtD
Epinephrine—Nausea—Chlorambucil—hematologic cancer	4.75e-05	0.000366	CcSEcCtD
Epinephrine—Paraesthesia—Ifosfamide—hematologic cancer	4.75e-05	0.000366	CcSEcCtD
Epinephrine—Hyperglycaemia—Prednisone—hematologic cancer	4.75e-05	0.000366	CcSEcCtD
Epinephrine—Hyperhidrosis—Gemcitabine—hematologic cancer	4.73e-05	0.000365	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—hematologic cancer	4.72e-05	0.000364	CcSEcCtD
Epinephrine—Somnolence—Ifosfamide—hematologic cancer	4.7e-05	0.000363	CcSEcCtD
Epinephrine—Insomnia—Vincristine—hematologic cancer	4.66e-05	0.00036	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Carmustine—hematologic cancer	4.66e-05	0.00036	CcSEcCtD
Epinephrine—Vomiting—Vinblastine—hematologic cancer	4.66e-05	0.000359	CcSEcCtD
Epinephrine—Nausea—Nilotinib—hematologic cancer	4.65e-05	0.000358	CcSEcCtD
Epinephrine—Erythema—Triamcinolone—hematologic cancer	4.64e-05	0.000358	CcSEcCtD
Epinephrine—Renal impairment—Doxorubicin—hematologic cancer	4.63e-05	0.000357	CcSEcCtD
Epinephrine—Paraesthesia—Vincristine—hematologic cancer	4.63e-05	0.000357	CcSEcCtD
Epinephrine—Acute coronary syndrome—Prednisone—hematologic cancer	4.63e-05	0.000357	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Alitretinoin—hematologic cancer	4.62e-05	0.000356	CcSEcCtD
Epinephrine—Nausea—Imatinib—hematologic cancer	4.62e-05	0.000356	CcSEcCtD
Epinephrine—Myocardial infarction—Prednisone—hematologic cancer	4.6e-05	0.000355	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Ifosfamide—hematologic cancer	4.57e-05	0.000352	CcSEcCtD
Epinephrine—Insomnia—Irinotecan—hematologic cancer	4.54e-05	0.00035	CcSEcCtD
Epinephrine—Nausea—Cladribine—hematologic cancer	4.54e-05	0.00035	CcSEcCtD
Epinephrine—Hypoglycaemia—Doxorubicin—hematologic cancer	4.52e-05	0.000348	CcSEcCtD
Epinephrine—Paraesthesia—Mitoxantrone—hematologic cancer	4.51e-05	0.000348	CcSEcCtD
Epinephrine—Paraesthesia—Irinotecan—hematologic cancer	4.51e-05	0.000348	CcSEcCtD
Epinephrine—Cerebrovascular accident—Doxorubicin—hematologic cancer	4.5e-05	0.000347	CcSEcCtD
Epinephrine—Dizziness—Lenalidomide—hematologic cancer	4.48e-05	0.000346	CcSEcCtD
Epinephrine—Nervous system disorder—Cisplatin—hematologic cancer	4.47e-05	0.000345	CcSEcCtD
Epinephrine—Somnolence—Mitoxantrone—hematologic cancer	4.47e-05	0.000344	CcSEcCtD
Epinephrine—Somnolence—Irinotecan—hematologic cancer	4.47e-05	0.000344	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Vincristine—hematologic cancer	4.45e-05	0.000343	CcSEcCtD
Epinephrine—Tachycardia—Cisplatin—hematologic cancer	4.45e-05	0.000343	CcSEcCtD
Epinephrine—Vomiting—Melphalan—hematologic cancer	4.43e-05	0.000342	CcSEcCtD
Epinephrine—Skin disorder—Cisplatin—hematologic cancer	4.43e-05	0.000342	CcSEcCtD
Epinephrine—Insomnia—Gemcitabine—hematologic cancer	4.43e-05	0.000341	CcSEcCtD
Epinephrine—Hypertension—Etoposide—hematologic cancer	4.42e-05	0.000341	CcSEcCtD
Epinephrine—Dizziness—Hydroxyurea—hematologic cancer	4.42e-05	0.000341	CcSEcCtD
Epinephrine—Hyperhidrosis—Cisplatin—hematologic cancer	4.41e-05	0.00034	CcSEcCtD
Epinephrine—Paraesthesia—Gemcitabine—hematologic cancer	4.39e-05	0.000339	CcSEcCtD
Epinephrine—Hypertension—Prednisolone—hematologic cancer	4.36e-05	0.000336	CcSEcCtD
Epinephrine—Chest pain—Etoposide—hematologic cancer	4.36e-05	0.000336	CcSEcCtD
Epinephrine—Nausea—Vinblastine—hematologic cancer	4.35e-05	0.000336	CcSEcCtD
Epinephrine—Somnolence—Gemcitabine—hematologic cancer	4.35e-05	0.000336	CcSEcCtD
Epinephrine—Hypokalaemia—Epirubicin—hematologic cancer	4.34e-05	0.000334	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Irinotecan—hematologic cancer	4.34e-05	0.000334	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—hematologic cancer	4.33e-05	0.000334	CcSEcCtD
Epinephrine—Arrhythmia—Dexamethasone—hematologic cancer	4.32e-05	0.000333	CcSEcCtD
Epinephrine—Arrhythmia—Betamethasone—hematologic cancer	4.32e-05	0.000333	CcSEcCtD
Epinephrine—Vomiting—Lenalidomide—hematologic cancer	4.31e-05	0.000332	CcSEcCtD
Epinephrine—Vomiting—Hydroxyurea—hematologic cancer	4.25e-05	0.000328	CcSEcCtD
Epinephrine—Haemoglobin—Prednisone—hematologic cancer	4.24e-05	0.000327	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Gemcitabine—hematologic cancer	4.22e-05	0.000326	CcSEcCtD
Epinephrine—Haemorrhage—Prednisone—hematologic cancer	4.21e-05	0.000325	CcSEcCtD
Epinephrine—Erythema—Betamethasone—hematologic cancer	4.21e-05	0.000325	CcSEcCtD
Epinephrine—Erythema—Dexamethasone—hematologic cancer	4.21e-05	0.000325	CcSEcCtD
Epinephrine—Hallucination—Prednisone—hematologic cancer	4.19e-05	0.000323	CcSEcCtD
Epinephrine—Nausea—Melphalan—hematologic cancer	4.14e-05	0.000319	CcSEcCtD
Epinephrine—Dizziness—Bortezomib—hematologic cancer	4.12e-05	0.000318	CcSEcCtD
Epinephrine—Paraesthesia—Cisplatin—hematologic cancer	4.09e-05	0.000316	CcSEcCtD
Epinephrine—Tachycardia—Etoposide—hematologic cancer	4.08e-05	0.000315	CcSEcCtD
Epinephrine—Skin disorder—Etoposide—hematologic cancer	4.06e-05	0.000313	CcSEcCtD
Epinephrine—Hyperhidrosis—Etoposide—hematologic cancer	4.04e-05	0.000312	CcSEcCtD
Epinephrine—Dizziness—Vinorelbine—hematologic cancer	4.03e-05	0.000311	CcSEcCtD
Epinephrine—Nausea—Lenalidomide—hematologic cancer	4.03e-05	0.000311	CcSEcCtD
Epinephrine—Tachycardia—Prednisolone—hematologic cancer	4.02e-05	0.00031	CcSEcCtD
Epinephrine—Hypokalaemia—Doxorubicin—hematologic cancer	4.01e-05	0.00031	CcSEcCtD
Epinephrine—Hypertension—Triamcinolone—hematologic cancer	4.01e-05	0.000309	CcSEcCtD
Epinephrine—Hyperhidrosis—Prednisolone—hematologic cancer	3.98e-05	0.000307	CcSEcCtD
Epinephrine—Nausea—Hydroxyurea—hematologic cancer	3.97e-05	0.000306	CcSEcCtD
Epinephrine—Vomiting—Bortezomib—hematologic cancer	3.97e-05	0.000306	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Cisplatin—hematologic cancer	3.94e-05	0.000304	CcSEcCtD
Epinephrine—Vomiting—Bleomycin—hematologic cancer	3.94e-05	0.000304	CcSEcCtD
Epinephrine—Drowsiness—Methotrexate—hematologic cancer	3.92e-05	0.000303	CcSEcCtD
Epinephrine—Flushing—Prednisone—hematologic cancer	3.91e-05	0.000302	CcSEcCtD
Epinephrine—Vomiting—Vinorelbine—hematologic cancer	3.87e-05	0.000299	CcSEcCtD
Epinephrine—Renal failure—Methotrexate—hematologic cancer	3.86e-05	0.000298	CcSEcCtD
Epinephrine—Dizziness—Thiotepa—hematologic cancer	3.85e-05	0.000297	CcSEcCtD
Epinephrine—Arrhythmia—Prednisone—hematologic cancer	3.76e-05	0.00029	CcSEcCtD
Epinephrine—Sweating—Methotrexate—hematologic cancer	3.76e-05	0.00029	CcSEcCtD
Epinephrine—Paraesthesia—Etoposide—hematologic cancer	3.75e-05	0.000289	CcSEcCtD
Epinephrine—Insomnia—Prednisolone—hematologic cancer	3.73e-05	0.000287	CcSEcCtD
Epinephrine—Dizziness—Thalidomide—hematologic cancer	3.72e-05	0.000287	CcSEcCtD
Epinephrine—Hyperglycaemia—Epirubicin—hematologic cancer	3.71e-05	0.000287	CcSEcCtD
Epinephrine—Somnolence—Etoposide—hematologic cancer	3.71e-05	0.000286	CcSEcCtD
Epinephrine—Nausea—Bortezomib—hematologic cancer	3.7e-05	0.000286	CcSEcCtD
Epinephrine—Paraesthesia—Prednisolone—hematologic cancer	3.7e-05	0.000285	CcSEcCtD
Epinephrine—Tachycardia—Triamcinolone—hematologic cancer	3.7e-05	0.000285	CcSEcCtD
Epinephrine—Vomiting—Thiotepa—hematologic cancer	3.7e-05	0.000285	CcSEcCtD
Epinephrine—Mental disorder—Prednisone—hematologic cancer	3.69e-05	0.000285	CcSEcCtD
Epinephrine—Nausea—Bleomycin—hematologic cancer	3.68e-05	0.000284	CcSEcCtD
Epinephrine—Drowsiness—Epirubicin—hematologic cancer	3.67e-05	0.000283	CcSEcCtD
Epinephrine—Erythema—Prednisone—hematologic cancer	3.67e-05	0.000283	CcSEcCtD
Epinephrine—Hyperhidrosis—Triamcinolone—hematologic cancer	3.66e-05	0.000283	CcSEcCtD
Epinephrine—Hypertension—Betamethasone—hematologic cancer	3.64e-05	0.000281	CcSEcCtD
Epinephrine—Hypertension—Dexamethasone—hematologic cancer	3.64e-05	0.000281	CcSEcCtD
Epinephrine—Nausea—Vinorelbine—hematologic cancer	3.62e-05	0.000279	CcSEcCtD
Epinephrine—Renal failure—Epirubicin—hematologic cancer	3.61e-05	0.000278	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Etoposide—hematologic cancer	3.61e-05	0.000278	CcSEcCtD
Epinephrine—Vomiting—Thalidomide—hematologic cancer	3.58e-05	0.000276	CcSEcCtD
Epinephrine—Dizziness—Carmustine—hematologic cancer	3.57e-05	0.000276	CcSEcCtD
Epinephrine—Haemoglobin—Methotrexate—hematologic cancer	3.54e-05	0.000273	CcSEcCtD
Epinephrine—Dizziness—Alitretinoin—hematologic cancer	3.54e-05	0.000273	CcSEcCtD
Epinephrine—Haemorrhage—Methotrexate—hematologic cancer	3.52e-05	0.000272	CcSEcCtD
Epinephrine—Sweating—Epirubicin—hematologic cancer	3.52e-05	0.000272	CcSEcCtD
Epinephrine—Dizziness—Ifosfamide—hematologic cancer	3.5e-05	0.00027	CcSEcCtD
Epinephrine—Nausea—Thiotepa—hematologic cancer	3.45e-05	0.000266	CcSEcCtD
Epinephrine—Hyperglycaemia—Doxorubicin—hematologic cancer	3.44e-05	0.000265	CcSEcCtD
Epinephrine—Vomiting—Carmustine—hematologic cancer	3.44e-05	0.000265	CcSEcCtD
Epinephrine—Insomnia—Triamcinolone—hematologic cancer	3.43e-05	0.000264	CcSEcCtD
Epinephrine—Dizziness—Vincristine—hematologic cancer	3.41e-05	0.000263	CcSEcCtD
Epinephrine—Vomiting—Alitretinoin—hematologic cancer	3.4e-05	0.000262	CcSEcCtD
Epinephrine—Paraesthesia—Triamcinolone—hematologic cancer	3.4e-05	0.000262	CcSEcCtD
Epinephrine—Drowsiness—Doxorubicin—hematologic cancer	3.4e-05	0.000262	CcSEcCtD
Epinephrine—Nervous system disorder—Betamethasone—hematologic cancer	3.37e-05	0.00026	CcSEcCtD
Epinephrine—Nervous system disorder—Dexamethasone—hematologic cancer	3.37e-05	0.00026	CcSEcCtD
Epinephrine—Agitation—Prednisone—hematologic cancer	3.37e-05	0.00026	CcSEcCtD
Epinephrine—Vomiting—Ifosfamide—hematologic cancer	3.36e-05	0.000259	CcSEcCtD
Epinephrine—Tachycardia—Dexamethasone—hematologic cancer	3.36e-05	0.000259	CcSEcCtD
Epinephrine—Tachycardia—Betamethasone—hematologic cancer	3.36e-05	0.000259	CcSEcCtD
Epinephrine—Nausea—Thalidomide—hematologic cancer	3.34e-05	0.000258	CcSEcCtD
Epinephrine—Renal failure—Doxorubicin—hematologic cancer	3.34e-05	0.000258	CcSEcCtD
Epinephrine—Hyperhidrosis—Betamethasone—hematologic cancer	3.32e-05	0.000256	CcSEcCtD
Epinephrine—Hyperhidrosis—Dexamethasone—hematologic cancer	3.32e-05	0.000256	CcSEcCtD
Epinephrine—Dizziness—Irinotecan—hematologic cancer	3.32e-05	0.000256	CcSEcCtD
Epinephrine—Haemoglobin—Epirubicin—hematologic cancer	3.31e-05	0.000256	CcSEcCtD
Epinephrine—Haemorrhage—Epirubicin—hematologic cancer	3.3e-05	0.000254	CcSEcCtD
Epinephrine—Hypoaesthesia—Epirubicin—hematologic cancer	3.28e-05	0.000253	CcSEcCtD
Epinephrine—Vomiting—Vincristine—hematologic cancer	3.28e-05	0.000253	CcSEcCtD
Epinephrine—Sweating—Doxorubicin—hematologic cancer	3.26e-05	0.000251	CcSEcCtD
Epinephrine—Nausea—Carmustine—hematologic cancer	3.21e-05	0.000248	CcSEcCtD
Epinephrine—Vomiting—Mitoxantrone—hematologic cancer	3.19e-05	0.000246	CcSEcCtD
Epinephrine—Vomiting—Irinotecan—hematologic cancer	3.19e-05	0.000246	CcSEcCtD
Epinephrine—Nausea—Alitretinoin—hematologic cancer	3.18e-05	0.000245	CcSEcCtD
Epinephrine—Hypertension—Prednisone—hematologic cancer	3.17e-05	0.000244	CcSEcCtD
Epinephrine—Nausea—Ifosfamide—hematologic cancer	3.14e-05	0.000242	CcSEcCtD
Epinephrine—Vomiting—Gemcitabine—hematologic cancer	3.11e-05	0.00024	CcSEcCtD
Epinephrine—Insomnia—Dexamethasone—hematologic cancer	3.11e-05	0.00024	CcSEcCtD
Epinephrine—Insomnia—Betamethasone—hematologic cancer	3.11e-05	0.00024	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	3.1e-05	0.000239	CcSEcCtD
Epinephrine—Paraesthesia—Betamethasone—hematologic cancer	3.09e-05	0.000238	CcSEcCtD
Epinephrine—Paraesthesia—Dexamethasone—hematologic cancer	3.09e-05	0.000238	CcSEcCtD
Epinephrine—Mental disorder—Methotrexate—hematologic cancer	3.09e-05	0.000238	CcSEcCtD
Epinephrine—Erythema—Methotrexate—hematologic cancer	3.07e-05	0.000237	CcSEcCtD
Epinephrine—Haemoglobin—Doxorubicin—hematologic cancer	3.07e-05	0.000236	CcSEcCtD
Epinephrine—Nausea—Vincristine—hematologic cancer	3.06e-05	0.000236	CcSEcCtD
Epinephrine—Flushing—Epirubicin—hematologic cancer	3.06e-05	0.000236	CcSEcCtD
Epinephrine—Haemorrhage—Doxorubicin—hematologic cancer	3.05e-05	0.000235	CcSEcCtD
Epinephrine—Hypoaesthesia—Doxorubicin—hematologic cancer	3.03e-05	0.000234	CcSEcCtD
Epinephrine—Nausea—Mitoxantrone—hematologic cancer	2.98e-05	0.00023	CcSEcCtD
Epinephrine—Nausea—Irinotecan—hematologic cancer	2.98e-05	0.00023	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	2.97e-05	0.000229	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Betamethasone—hematologic cancer	2.97e-05	0.000229	CcSEcCtD
Epinephrine—Arrhythmia—Epirubicin—hematologic cancer	2.94e-05	0.000227	CcSEcCtD
Epinephrine—Nervous system disorder—Prednisone—hematologic cancer	2.94e-05	0.000227	CcSEcCtD
Epinephrine—Tachycardia—Prednisone—hematologic cancer	2.92e-05	0.000225	CcSEcCtD
Epinephrine—Skin disorder—Prednisone—hematologic cancer	2.91e-05	0.000224	CcSEcCtD
Epinephrine—Nausea—Gemcitabine—hematologic cancer	2.91e-05	0.000224	CcSEcCtD
Epinephrine—Vomiting—Cisplatin—hematologic cancer	2.9e-05	0.000224	CcSEcCtD
Epinephrine—Hyperhidrosis—Prednisone—hematologic cancer	2.89e-05	0.000223	CcSEcCtD
Epinephrine—Mental disorder—Epirubicin—hematologic cancer	2.89e-05	0.000223	CcSEcCtD
Epinephrine—Erythema—Epirubicin—hematologic cancer	2.87e-05	0.000221	CcSEcCtD
Epinephrine—Flushing—Doxorubicin—hematologic cancer	2.83e-05	0.000218	CcSEcCtD
Epinephrine—Tension—Epirubicin—hematologic cancer	2.82e-05	0.000217	CcSEcCtD
Epinephrine—Nervousness—Epirubicin—hematologic cancer	2.79e-05	0.000215	CcSEcCtD
Epinephrine—Dizziness—Etoposide—hematologic cancer	2.76e-05	0.000213	CcSEcCtD
Epinephrine—Dizziness—Prednisolone—hematologic cancer	2.72e-05	0.00021	CcSEcCtD
Epinephrine—Arrhythmia—Doxorubicin—hematologic cancer	2.72e-05	0.00021	CcSEcCtD
Epinephrine—Nausea—Cisplatin—hematologic cancer	2.71e-05	0.000209	CcSEcCtD
Epinephrine—Insomnia—Prednisone—hematologic cancer	2.71e-05	0.000209	CcSEcCtD
Epinephrine—Paraesthesia—Prednisone—hematologic cancer	2.69e-05	0.000207	CcSEcCtD
Epinephrine—Mental disorder—Doxorubicin—hematologic cancer	2.67e-05	0.000206	CcSEcCtD
Epinephrine—Vomiting—Etoposide—hematologic cancer	2.66e-05	0.000205	CcSEcCtD
Epinephrine—Erythema—Doxorubicin—hematologic cancer	2.65e-05	0.000205	CcSEcCtD
Epinephrine—Agitation—Epirubicin—hematologic cancer	2.64e-05	0.000203	CcSEcCtD
Epinephrine—Chest pain—Methotrexate—hematologic cancer	2.61e-05	0.000201	CcSEcCtD
Epinephrine—Tension—Doxorubicin—hematologic cancer	2.61e-05	0.000201	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	2.59e-05	0.0002	CcSEcCtD
Epinephrine—Nervousness—Doxorubicin—hematologic cancer	2.58e-05	0.000199	CcSEcCtD
Epinephrine—Palpitations—Epirubicin—hematologic cancer	2.54e-05	0.000196	CcSEcCtD
Epinephrine—Dizziness—Triamcinolone—hematologic cancer	2.51e-05	0.000193	CcSEcCtD
Epinephrine—Nausea—Etoposide—hematologic cancer	2.48e-05	0.000191	CcSEcCtD
Epinephrine—Hypertension—Epirubicin—hematologic cancer	2.48e-05	0.000191	CcSEcCtD
Epinephrine—Nervous system disorder—Methotrexate—hematologic cancer	2.45e-05	0.000189	CcSEcCtD
Epinephrine—Nausea—Prednisolone—hematologic cancer	2.45e-05	0.000189	CcSEcCtD
Epinephrine—Chest pain—Epirubicin—hematologic cancer	2.44e-05	0.000188	CcSEcCtD
Epinephrine—Agitation—Doxorubicin—hematologic cancer	2.44e-05	0.000188	CcSEcCtD
Epinephrine—Skin disorder—Methotrexate—hematologic cancer	2.43e-05	0.000187	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.43e-05	0.000187	CcSEcCtD
Epinephrine—Hyperhidrosis—Methotrexate—hematologic cancer	2.42e-05	0.000187	CcSEcCtD
Epinephrine—Vomiting—Triamcinolone—hematologic cancer	2.41e-05	0.000186	CcSEcCtD
Epinephrine—Palpitations—Doxorubicin—hematologic cancer	2.35e-05	0.000181	CcSEcCtD
Epinephrine—Nervous system disorder—Epirubicin—hematologic cancer	2.3e-05	0.000177	CcSEcCtD
Epinephrine—Hypertension—Doxorubicin—hematologic cancer	2.29e-05	0.000177	CcSEcCtD
Epinephrine—Tachycardia—Epirubicin—hematologic cancer	2.29e-05	0.000176	CcSEcCtD
Epinephrine—Skin disorder—Epirubicin—hematologic cancer	2.27e-05	0.000175	CcSEcCtD
Epinephrine—Dizziness—Betamethasone—hematologic cancer	2.27e-05	0.000175	CcSEcCtD
Epinephrine—Dizziness—Dexamethasone—hematologic cancer	2.27e-05	0.000175	CcSEcCtD
Epinephrine—Hyperhidrosis—Epirubicin—hematologic cancer	2.26e-05	0.000175	CcSEcCtD
Epinephrine—Insomnia—Methotrexate—hematologic cancer	2.26e-05	0.000175	CcSEcCtD
Epinephrine—Chest pain—Doxorubicin—hematologic cancer	2.26e-05	0.000174	CcSEcCtD
Epinephrine—Nausea—Triamcinolone—hematologic cancer	2.25e-05	0.000174	CcSEcCtD
Epinephrine—Paraesthesia—Methotrexate—hematologic cancer	2.25e-05	0.000173	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.24e-05	0.000173	CcSEcCtD
Epinephrine—Somnolence—Methotrexate—hematologic cancer	2.22e-05	0.000172	CcSEcCtD
Epinephrine—Vomiting—Betamethasone—hematologic cancer	2.19e-05	0.000169	CcSEcCtD
Epinephrine—Vomiting—Dexamethasone—hematologic cancer	2.19e-05	0.000169	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.16e-05	0.000167	CcSEcCtD
Epinephrine—Nervous system disorder—Doxorubicin—hematologic cancer	2.12e-05	0.000164	CcSEcCtD
Epinephrine—Insomnia—Epirubicin—hematologic cancer	2.12e-05	0.000163	CcSEcCtD
Epinephrine—Tachycardia—Doxorubicin—hematologic cancer	2.11e-05	0.000163	CcSEcCtD
Epinephrine—Skin disorder—Doxorubicin—hematologic cancer	2.1e-05	0.000162	CcSEcCtD
Epinephrine—Paraesthesia—Epirubicin—hematologic cancer	2.1e-05	0.000162	CcSEcCtD
Epinephrine—Hyperhidrosis—Doxorubicin—hematologic cancer	2.09e-05	0.000162	CcSEcCtD
Epinephrine—Somnolence—Epirubicin—hematologic cancer	2.08e-05	0.000161	CcSEcCtD
Epinephrine—Nausea—Dexamethasone—hematologic cancer	2.04e-05	0.000158	CcSEcCtD
Epinephrine—Nausea—Betamethasone—hematologic cancer	2.04e-05	0.000158	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.02e-05	0.000156	CcSEcCtD
Epinephrine—Dizziness—Prednisone—hematologic cancer	1.98e-05	0.000153	CcSEcCtD
Epinephrine—Insomnia—Doxorubicin—hematologic cancer	1.96e-05	0.000151	CcSEcCtD
Epinephrine—Paraesthesia—Doxorubicin—hematologic cancer	1.95e-05	0.00015	CcSEcCtD
Epinephrine—Somnolence—Doxorubicin—hematologic cancer	1.93e-05	0.000149	CcSEcCtD
Epinephrine—Vomiting—Prednisone—hematologic cancer	1.9e-05	0.000147	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.87e-05	0.000144	CcSEcCtD
Epinephrine—Nausea—Prednisone—hematologic cancer	1.78e-05	0.000137	CcSEcCtD
Epinephrine—Dizziness—Methotrexate—hematologic cancer	1.65e-05	0.000128	CcSEcCtD
Epinephrine—Vomiting—Methotrexate—hematologic cancer	1.59e-05	0.000123	CcSEcCtD
Epinephrine—Dizziness—Epirubicin—hematologic cancer	1.55e-05	0.000119	CcSEcCtD
Epinephrine—Vomiting—Epirubicin—hematologic cancer	1.49e-05	0.000115	CcSEcCtD
Epinephrine—Nausea—Methotrexate—hematologic cancer	1.49e-05	0.000115	CcSEcCtD
Epinephrine—Dizziness—Doxorubicin—hematologic cancer	1.43e-05	0.000111	CcSEcCtD
Epinephrine—Nausea—Epirubicin—hematologic cancer	1.39e-05	0.000107	CcSEcCtD
Epinephrine—Vomiting—Doxorubicin—hematologic cancer	1.38e-05	0.000106	CcSEcCtD
Epinephrine—Nausea—Doxorubicin—hematologic cancer	1.29e-05	9.93e-05	CcSEcCtD
Epinephrine—ADRB1—Signaling Pathways—JUN—hematologic cancer	1.01e-06	9.9e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—FGF2—hematologic cancer	1e-06	9.85e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CCND1—hematologic cancer	1e-06	9.83e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—JUN—hematologic cancer	1e-06	9.81e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—HRAS—hematologic cancer	9.98e-07	9.8e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—SRC—hematologic cancer	9.93e-07	9.75e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CD44—hematologic cancer	9.92e-07	9.74e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—NQO1—hematologic cancer	9.92e-07	9.74e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PIK3R1—hematologic cancer	9.9e-07	9.72e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CCND1—hematologic cancer	9.89e-07	9.71e-06	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—EP300—hematologic cancer	9.87e-07	9.69e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—JUN—hematologic cancer	9.87e-07	9.69e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—NCOR1—hematologic cancer	9.85e-07	9.67e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—GSTM1—hematologic cancer	9.85e-07	9.67e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—HRAS—hematologic cancer	9.82e-07	9.64e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CDKN1B—hematologic cancer	9.81e-07	9.63e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MAP2K1—hematologic cancer	9.8e-07	9.62e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—CDKN1A—hematologic cancer	9.78e-07	9.6e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—PTEN—hematologic cancer	9.76e-07	9.58e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PIK3CD—hematologic cancer	9.74e-07	9.56e-06	CbGpPWpGaD
Epinephrine—ADRA2C—GPCR downstream signaling—AKT1—hematologic cancer	9.7e-07	9.52e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CDKN1A—hematologic cancer	9.69e-07	9.51e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—VEGFA—hematologic cancer	9.67e-07	9.5e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—PTEN—hematologic cancer	9.67e-07	9.49e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CDKN1B—hematologic cancer	9.65e-07	9.48e-06	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	9.65e-07	9.47e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—JAK2—hematologic cancer	9.62e-07	9.44e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CASP3—hematologic cancer	9.61e-07	9.44e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—IL2—hematologic cancer	9.6e-07	9.42e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—STAT3—hematologic cancer	9.58e-07	9.4e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CDKN1A—hematologic cancer	9.57e-07	9.39e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—NRAS—hematologic cancer	9.55e-07	9.38e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—IL6—hematologic cancer	9.55e-07	9.38e-06	CbGpPWpGaD
Epinephrine—ADRA1B—GPCR downstream signaling—AKT1—hematologic cancer	9.55e-07	9.37e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MAPK8—hematologic cancer	9.55e-07	9.37e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—PTEN—hematologic cancer	9.54e-07	9.37e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—KRAS—hematologic cancer	9.53e-07	9.36e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—AKT1—hematologic cancer	9.52e-07	9.35e-06	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—AKT1—hematologic cancer	9.47e-07	9.3e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CASP3—hematologic cancer	9.46e-07	9.29e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MAPK8—hematologic cancer	9.46e-07	9.29e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—IL2—hematologic cancer	9.45e-07	9.27e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—AKT1—hematologic cancer	9.43e-07	9.26e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—PIK3CA—hematologic cancer	9.43e-07	9.26e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—IL6—hematologic cancer	9.4e-07	9.23e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MDM2—hematologic cancer	9.39e-07	9.22e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CYCS—hematologic cancer	9.38e-07	9.21e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CCND1—hematologic cancer	9.36e-07	9.19e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MAPK8—hematologic cancer	9.34e-07	9.17e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—JUN—hematologic cancer	9.34e-07	9.17e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	9.33e-07	9.15e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—FGF2—hematologic cancer	9.32e-07	9.15e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—AKT1—hematologic cancer	9.31e-07	9.14e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—EP300—hematologic cancer	9.31e-07	9.14e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—EP300—hematologic cancer	9.22e-07	9.05e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CCND1—hematologic cancer	9.21e-07	9.04e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PIK3R1—hematologic cancer	9.2e-07	9.03e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—JUN—hematologic cancer	9.19e-07	9.02e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—MAPK3—hematologic cancer	9.15e-07	8.98e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PIK3CB—hematologic cancer	9.14e-07	8.97e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MTOR—hematologic cancer	9.14e-07	8.97e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—EP300—hematologic cancer	9.1e-07	8.94e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CDKN1A—hematologic cancer	9.05e-07	8.89e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—SRC—hematologic cancer	9.05e-07	8.88e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—PTEN—hematologic cancer	9.03e-07	8.87e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	8.98e-07	8.81e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—SRC—hematologic cancer	8.97e-07	8.8e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	8.94e-07	8.77e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CDKN1A—hematologic cancer	8.91e-07	8.75e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—MYC—hematologic cancer	8.9e-07	8.74e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—PTEN—hematologic cancer	8.89e-07	8.73e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—TGFB1—hematologic cancer	8.88e-07	8.72e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—SRC—hematologic cancer	8.85e-07	8.69e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MAPK8—hematologic cancer	8.83e-07	8.67e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—VEGFA—hematologic cancer	8.81e-07	8.65e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—AKT1—hematologic cancer	8.81e-07	8.65e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—PTEN—hematologic cancer	8.77e-07	8.61e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	8.76e-07	8.6e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—VEGFA—hematologic cancer	8.73e-07	8.57e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—STAT3—hematologic cancer	8.73e-07	8.57e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	8.72e-07	8.57e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	8.72e-07	8.56e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—NRAS—hematologic cancer	8.71e-07	8.55e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—MTHFR—hematologic cancer	8.7e-07	8.55e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MAPK8—hematologic cancer	8.69e-07	8.54e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—AKT1—hematologic cancer	8.67e-07	8.51e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—STAT3—hematologic cancer	8.65e-07	8.49e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—NRAS—hematologic cancer	8.63e-07	8.47e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	8.62e-07	8.46e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—EP300—hematologic cancer	8.61e-07	8.46e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	8.57e-07	8.42e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PIK3CG—hematologic cancer	8.56e-07	8.4e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—STAT3—hematologic cancer	8.54e-07	8.38e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—NRAS—hematologic cancer	8.52e-07	8.36e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	8.49e-07	8.33e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	8.49e-07	8.33e-06	CbGpPWpGaD
Epinephrine—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	8.48e-07	8.33e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—EP300—hematologic cancer	8.48e-07	8.32e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	8.4e-07	8.25e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—IL2—hematologic cancer	8.39e-07	8.24e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—SRC—hematologic cancer	8.38e-07	8.22e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—EP300—hematologic cancer	8.37e-07	8.21e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	8.35e-07	8.2e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	8.34e-07	8.18e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—GSTP1—hematologic cancer	8.27e-07	8.12e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	8.26e-07	8.11e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—SRC—hematologic cancer	8.24e-07	8.09e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—KRAS—hematologic cancer	8.22e-07	8.07e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	8.18e-07	8.03e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—JUN—hematologic cancer	8.16e-07	8.01e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—VEGFA—hematologic cancer	8.16e-07	8.01e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	8.16e-07	8.01e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MYC—hematologic cancer	8.11e-07	7.96e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	8.1e-07	7.96e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	8.09e-07	7.94e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—STAT3—hematologic cancer	8.08e-07	7.93e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—NRAS—hematologic cancer	8.06e-07	7.91e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MYC—hematologic cancer	8.03e-07	7.89e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	8.03e-07	7.88e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	8.01e-07	7.87e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	7.97e-07	7.82e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	7.95e-07	7.8e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—CREBBP—hematologic cancer	7.94e-07	7.79e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MYC—hematologic cancer	7.93e-07	7.79e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	7.93e-07	7.78e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	7.91e-07	7.77e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	7.91e-07	7.77e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	7.89e-07	7.75e-06	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	7.88e-07	7.74e-06	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—PIK3CA—hematologic cancer	7.83e-07	7.69e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—ABCB1—hematologic cancer	7.83e-07	7.69e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	7.81e-07	7.67e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—IL2—hematologic cancer	7.8e-07	7.65e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	7.76e-07	7.62e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	7.72e-07	7.58e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	7.72e-07	7.58e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	7.7e-07	7.56e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	7.67e-07	7.53e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—PIK3CA—hematologic cancer	7.62e-07	7.48e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—NCOR1—hematologic cancer	7.6e-07	7.46e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—GSTM1—hematologic cancer	7.6e-07	7.46e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	7.6e-07	7.46e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	7.59e-07	7.46e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—JUN—hematologic cancer	7.58e-07	7.45e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—PIK3CA—hematologic cancer	7.55e-07	7.42e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—EP300—hematologic cancer	7.53e-07	7.39e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PIK3CD—hematologic cancer	7.52e-07	7.39e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MYC—hematologic cancer	7.5e-07	7.37e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—KRAS—hematologic cancer	7.49e-07	7.36e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	7.49e-07	7.35e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—ALB—hematologic cancer	7.43e-07	7.29e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	7.42e-07	7.29e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MYC—hematologic cancer	7.39e-07	7.25e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	7.37e-07	7.23e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	7.35e-07	7.22e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	7.34e-07	7.2e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—KRAS—hematologic cancer	7.33e-07	7.2e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—SRC—hematologic cancer	7.32e-07	7.19e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PIK3CG—hematologic cancer	7.31e-07	7.18e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—TP53—hematologic cancer	7.31e-07	7.18e-06	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—PIK3CA—hematologic cancer	7.3e-07	7.17e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	7.18e-07	7.04e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	7.16e-07	7.03e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	7.13e-07	7e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PIK3R1—hematologic cancer	7.1e-07	6.98e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	7.06e-07	6.93e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	7.04e-07	6.91e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—EP300—hematologic cancer	7e-07	6.87e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—HRAS—hematologic cancer	6.99e-07	6.86e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	6.93e-07	6.81e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	6.88e-07	6.76e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	6.82e-07	6.7e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	6.82e-07	6.7e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—SRC—hematologic cancer	6.8e-07	6.68e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—CREBBP—hematologic cancer	6.78e-07	6.66e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	6.75e-07	6.62e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	6.73e-07	6.61e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—MTHFR—hematologic cancer	6.72e-07	6.6e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—IL6—hematologic cancer	6.69e-07	6.57e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—TP53—hematologic cancer	6.66e-07	6.54e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	6.63e-07	6.5e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—TP53—hematologic cancer	6.6e-07	6.48e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MYC—hematologic cancer	6.56e-07	6.44e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	6.56e-07	6.44e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PIK3CB—hematologic cancer	6.56e-07	6.44e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	6.54e-07	6.43e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	6.54e-07	6.42e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—TP53—hematologic cancer	6.51e-07	6.4e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PIK3CD—hematologic cancer	6.43e-07	6.31e-06	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—AKT1—hematologic cancer	6.4e-07	6.28e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	6.37e-07	6.25e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—HRAS—hematologic cancer	6.37e-07	6.25e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—ALB—hematologic cancer	6.35e-07	6.23e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	6.31e-07	6.2e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	6.27e-07	6.16e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	6.27e-07	6.15e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—HRAS—hematologic cancer	6.23e-07	6.12e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—AKT1—hematologic cancer	6.22e-07	6.11e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—PIK3CA—hematologic cancer	6.19e-07	6.08e-06	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—AKT1—hematologic cancer	6.17e-07	6.06e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—TP53—hematologic cancer	6.16e-07	6.05e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MYC—hematologic cancer	6.1e-07	5.98e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—IL6—hematologic cancer	6.1e-07	5.98e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	6.08e-07	5.97e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PIK3R1—hematologic cancer	6.07e-07	5.96e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—TP53—hematologic cancer	6.07e-07	5.96e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	6.06e-07	5.95e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—IL6—hematologic cancer	6.04e-07	5.93e-06	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—AKT1—hematologic cancer	5.96e-07	5.86e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—IL6—hematologic cancer	5.96e-07	5.85e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	5.89e-07	5.79e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	5.8e-07	5.7e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PTEN—hematologic cancer	5.67e-07	5.56e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	5.64e-07	5.54e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—IL6—hematologic cancer	5.64e-07	5.54e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	5.63e-07	5.53e-06	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—AKT1—hematologic cancer	5.62e-07	5.52e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PIK3CB—hematologic cancer	5.6e-07	5.5e-06	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	5.57e-07	5.47e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	5.57e-07	5.47e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—IL6—hematologic cancer	5.55e-07	5.45e-06	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—AKT1—hematologic cancer	5.5e-07	5.4e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—EP300—hematologic cancer	5.4e-07	5.31e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—TP53—hematologic cancer	5.39e-07	5.29e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CREBBP—hematologic cancer	5.23e-07	5.14e-06	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	5.2e-07	5.11e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	5.17e-07	5.08e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	5.15e-07	5.06e-06	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	5.12e-07	5.03e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—AKT1—hematologic cancer	5.06e-07	4.96e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—TP53—hematologic cancer	5.01e-07	4.91e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	4.96e-07	4.87e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—IL6—hematologic cancer	4.93e-07	4.84e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—ALB—hematologic cancer	4.9e-07	4.81e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PTEN—hematologic cancer	4.84e-07	4.75e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	4.79e-07	4.7e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	4.69e-07	4.6e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—EP300—hematologic cancer	4.62e-07	4.53e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—IL6—hematologic cancer	4.58e-07	4.5e-06	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	4.55e-07	4.47e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	4.33e-07	4.25e-06	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	4.23e-07	4.15e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PIK3CA—hematologic cancer	4e-07	3.92e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PTEN—hematologic cancer	3.74e-07	3.67e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—EP300—hematologic cancer	3.56e-07	3.5e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PIK3CA—hematologic cancer	3.42e-07	3.35e-06	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—AKT1—hematologic cancer	3.27e-07	3.21e-06	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—AKT1—hematologic cancer	2.79e-07	2.74e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	2.64e-07	2.59e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—AKT1—hematologic cancer	2.15e-07	2.11e-06	CbGpPWpGaD
